WHO naming stem · suffix · 6 listed names
-ribine
This page was written with AI.
ribofuranyl-derivatives of the “pyrazofurin” type
Where it sits in a name
WHO writes the stem as -ribine. So the letters ribine sit at the end of the name (…ribine).
All 6 names WHO lists under -ribine
These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.
Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 1 of 6 names appears in these lists: 1 in the US list (FDA Drugs@FDA) and 1 in the EU central list (EMA); 1 has national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.
- azaribineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- cladribine
- isatoribineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- loxoribineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- mizoribineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- triciribineNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.
EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.
EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.
Same group, without the stem
WHO also lists these 5 names under -ribine: group (c) of Part IV of the 2024 stem book, “INN which belong to the same group of pharmaceutical substances but in which the stem is not used”. They belong to the same group of substances as the group (a) names above, yet they do not carry -ribine, so the name alone does not reveal the group.
- benaxibine
- pirazofurin
- ribavirin
- riboprine
- tiazofurine
Decode another name
Decoded
azaribine
Listed INNCarries 2 WHO stems, most specific first: -ribine …
- -ribineend of the nameWHO lists it hereWHO definition: ribofuranyl-derivatives of the “pyrazofurin” type
- -ibineend of the nameWHO lists it hereWHO definition: ribofuranyl-derivatives of the “pyrazofurin” type
“azaribine” is an INN that WHO lists under -ribine, -ibine in the 2024 stem book.
The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.
Source and licence
The definition of -ribine (Part II B) and the 6 names (Part IV, group (a)), and the 5 of the same group without the stem (group (c)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .
Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.